TRIPS – Treatment to Improve Depression and/or Anxiety Using Psilocybin-assisted Psychotherapy in Cancer Survivors

This open-label, Phase II trial (n=20) will investigate the feasibility, safety, and effects of psilocybin-assisted psychotherapy for cancer survivors experiencing depression and/or anxiety.

The study, sponsored by M.D. Anderson Cancer Center, aims to assess the treatment’s impact on quality of life, psychosocial well-being, and functional status. It will also examine changes in inflammatory markers and brain network integration through fMRI.

Participants will receive psilocybin in a structured therapeutic setting, with primary outcomes including treatment adherence and adverse event monitoring. The trial is set to begin in June 2025 and is expected to conclude by March 2029.

Topic Anxiety Depression PTSD
Compound Psilocybin
Country United States of America
Visit trial

Trial Details



Trial Number

Sponsors & Collaborators

National Cancer Institute
This company doesn't have a full profile yet, it is linked to a clinical trial.

University of Texas
The University of Texas is conducting research with psychedelics across locations in Houston, Austin, Dallas and San Antonio.

Data attribution

A large set of the trials in our database are sourced from ClinicalTrials.gov (CTG). We have modified these post to display the information in a more clear format or to correct spelling mistakes. Our database in actively updated and may show a different status (e.g. completed) if we have knowledge of this update (e.g. a published paper on the study) which isn't reflected yet on CTG. If a trial is not sourced from CTG, this is indicated on this page and you can follow the link to the alternative source of information.